Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Overview of attention for article published in Journal of Clinical Oncology, March 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 6 news outlets
blogs: 1 blog
twitter: 68 X users

patent: 6 patents
reddit: 1 Redditor

Readers on

mendeley: 109 Mendeley

So far, Altmetric has seen 9 news stories from 6 outlets.

Magrolimab/Azacitidine Shows Tolerability, Efficacy in Higher-Risk MDS

Cancer Network, 08 May 2023

Magrolimab may be a potentially tolerable and effective treatment in combination with azacitidine (Onureg) for patients with…

MD Anderson Research Highlights for March 29, 2023

EurekAlert!, 29 Mar 2023

HOUSTON ― The University of Texas MD Anderson Cancer Centers Research Highlights showcases the latest breakthroughs in cancer…

MD Anderson Research Highlights for March 29, 2023

Newswise, 29 Mar 2023

Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs…

MD Anderson Research Highlights for March 29, 2023

Sciencenewsnet.in, 29 Mar 2023

Post Views: 7 HOUSTON ― The University of Texas MD Anderson Cancer Centers Research Highlights showcases the latest…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 5 additional news stories.